Company Encyclopedia
View More
name
Goldman Sachs Future Health Care Equity ETF
GDOC.US
News
View More

Key facts: Eli Lilly's orforglipron achieves 12.4% weight loss; Zepbound surpasses Wegovy; Operating margin rises to 40.9%

Eli Lilly's orforglipron, a daily oral GLP-1 agonist, showed 12.4% weight loss in trials. The FDA application is submitted, with a planned price of $149 per month.12Eli Lilly's weight-loss drug Zepbound outperformed Novo Nordisk's Wegovy in a study, leading analysts to predict Zepbound will surpass Wegovy sales by 2025.3Eli Lilly's adjusted operating margin has risen by 20.8 percentage points over the past two years, now standing at 40.9% for the trailing 12 months, highlighting enhanced profitability.4

TradingView·
US
LLY
-0.48%
TradingView·
US
LLY
-0.48%

Top Pharmaceutical Stocks To Add to Your Watchlist - December 23rd

MarketBeat highlights seven pharmaceutical stocks to watch: Novo Nordisk, Eli Lilly, Pfizer, Bristol Myers Squibb, AbbVie, Abbott Laboratories, and Gilead Sciences. These companies are noted for their high trading volumes and potential for substantial returns, driven by factors like clinical trial results and regulatory approvals. However, they also carry risks such as volatility and regulatory challenges. The report provides insights into each company's focus areas and recent developments.

Market Beat·
US
NVO
+7.48%
US
LLY
-0.48%
US
ABT
-0.67%
Market Beat·
US
NVO
+7.48%
US
LLY
-0.48%
US
ABT
-0.67%

S&P 500 Set for Fresh Highs

The S&P 500 rose 0.5% on Tuesday, testing fresh record highs, with the Nasdaq and Dow also gaining. Technology and energy stocks led the advance, with Nvidia up 2.5%. Real estate and consumer staples underperformed. Eli Lilly shares fluctuated after FDA approved Novo Nordisk’s weight-loss pill. Strong economic data suggested the Fed may keep rates steady in January, with the US economy growing at 4.3% in Q3, the fastest in two years.

Trading Economics·
US
LLY
-0.48%
US
TGT
-1.07%
US
COST
+0.44%
Trading Economics·
US
LLY
-0.48%
US
TGT
-1.07%
US
COST
+0.44%

What's Going On With Eli Lilly Stock Today?

Eli Lilly's stock is down as investors assess competition from Novo Nordisk, which received FDA approval for an oral weight loss drug. Eli Lilly's injectable weight loss drug, Zepbound, faces competition, while its oral drug, orforglipron, is under review. Eli Lilly's stock is trading above its 20-day and 100-day SMAs, with a 34.51% increase over 12 months. Key support is at $977, resistance at $1,112. The stock is not overbought or oversold, but bearish pressure is noted.

benzinga_article·
US
NVO
+7.48%
US
LLY
-0.48%
benzinga_article·
US
NVO
+7.48%
US
LLY
-0.48%

Novo Nordisk Loses Weight-Loss Lead as Lilly Gains Ground

Novo Nordisk is facing increased competition in the obesity-drug market from Eli Lilly's Zepbound, which is projected to surpass Wegovy sales by 2025. Novo has also been impacted by lower-priced copycat GLP-1 products, leading to a cut in earnings outlook. The company is focusing on pricing discipline, cost controls, and new strategies, including a direct-to-patient platform. Novo's future pipeline includes a higher-dose Wegovy injection and an oral version expected in 2026. The company has also agreed to lower prices for Medicare and Medicaid patients, which may affect global sales growth.

GuruFocus·
US
LLY
-0.48%
US
NVO
+7.48%
GuruFocus·
US
LLY
-0.48%
US
NVO
+7.48%
© 2025 Longbridge｜Disclaimer